Role of atazanavir in the treatment of HIV infection

References

• Bristol Myers Squibb Company. Princeton, NJ 08543, USA. Reyataz product information. [Accessed 31 Aug 2008]. Available from: http://packageinserts.bms.com/pi/pi_reyataz.pdf
   Google Scholar
• ColonnoRThiryALimoliKParkinNActivities of atazanavir (BMS-232632) against a large panel of HIV type 1 clinical isolates resistant to one or more approved protease inhibitorsAntimicrob Agents Chemother20034741324133312654666
   PubMed Web of Science ®Google Scholar
• DrusanoGBilelloJPrestonSHollow-fiber unit evaluation of a new HIV type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variableJ Infect Dis200118371126112911237841
   PubMed Web of Science ®Google Scholar
• ColonnoRRoseRMcLarenCThiryAParkinNFriborgJIdentification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimensJ Infect Dis2004189101802181015122516
   PubMed Web of Science ®Google Scholar
• SquiresKLazzarinAGatellJMComparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose ZDV and lamivudine, as initial therapy for patients infected with HIVJ Acquir Immune Defic Syndr20043651011101915247553
   PubMed Web of Science ®Google Scholar
• SistaPWasikowskiBLecocqPPatteryTBachelerLThe HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contextsJ Clin Virol200842440540818472298
   PubMed Web of Science ®Google Scholar
• De MendozaCGarridoCCorralAChanging rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patientsAIDS Res Hum Retroviruses200723787988517678470
   PubMed Web of Science ®Google Scholar
• JohnsonVBrun-VezinetFClotetBUpdate of the drug resistance mutations in HIV-1: Spring 2008Top HIV Med2008161626818441382
   PubMedGoogle Scholar
• BarriosARendonALGallegoOPredictors of virological response to atazanavir in protease inhibitor-experienced patientsHIV Clin Trials20045420120515472794
   PubMed Web of Science ®Google Scholar
• StebbingJNathanBJonesRVirological failure and subsequent resistance profiles in individuals exposed to atazanavirAIDS200721131826182817690587
   PubMed Web of Science ®Google Scholar
• CuzinLFlandrePPugliesePAtazanavir in patients with persistent viral replication despite HAART: Results from the French prospective NADIS cohortHIV Clin Trials20089314715118547901
   PubMed Web of Science ®Google Scholar
• ShaferRSchapiroJHIV-1 drug resistance mutations: An updated framework for the second decade of HAARTAIDS Rev2008102678418615118
   PubMed Web of Science ®Google Scholar
• LatailladeMMolinaJMThiryAManciniMMcGrathDfor the BMS-AI424138 Study GroupThe CASTLE study 48 weeks results: The impact of HIV subtypes and baseline resistance on treatment outcomes and the emergence of resistanceAntivir Ther200813 suppl 3A135
   PubMedGoogle Scholar
• GoldsmithDPerryCAtazanavirDrugs2003631616799312904086
   PubMed Web of Science ®Google Scholar
• ColomboSBuclinTCavassiniMPopulation pharmacokinetics of atazanavir in patients with HIV infectionAntimicrob Agents Chemother200650113801380816940065
   PubMed Web of Science ®Google Scholar
• RutsteinRSamsonPKiserJThe PATCG 1020 protocol: Atazanavir with or without ritonavir in HIV-infected infants, children, and adolescents14th Conference on Retroviruses and Opportunistic Infections (CROI)2007 February 3–5Los Angeles, USAAbstract 715.
   Google Scholar
• BarreiroPRodriguez-NovoaSLabargaPInfluence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis CJ Infect Dis2007195797397917330787
   PubMed Web of Science ®Google Scholar
• MirochnickMCapparelliEPharmacokinetics of antiretrovirals in pregnant womenClin Pharmacokinet200443151071108715568888
   PubMed Web of Science ®Google Scholar
• EleyTVandeloiseEChildMSteady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once daily/ Ritonavir 100 mg once daily + ZDV/3TC during the third trimester in HIV+ women15th Conference on Retroviruses and Opportunistic Infections (CROI)2008 Feb 3–6Boston, USAAbstract 624.
   Google Scholar
• FerreiraCFloch-TudalCMeierFAtazanavir in pregnancy: Influence on neonatal hyperbilirubinemia15th Conference on Retro-viruses and Opportunistic Infections (CROI)2008 Feb 3–6Boston, USAAbstract 625.
   Google Scholar
• LuciaMGolottaCRutellaSRastrelliESavarinoACaudaRAtazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activityJ Acquir Immune Defic Syndr200539563563716044020
   PubMed Web of Science ®Google Scholar
• PerloffEDuanSSkolnikPGreenblattDvon MoltkeLAtazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitroDrug Metab Dispos200533676477015764714
   PubMed Web of Science ®Google Scholar
• La ProteCBackDBlaschkeTUpdated guidelines to perform therapeutic drug monitoring for antiretroviral agentsRev Antivir Ther20063314
   Google Scholar
• Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008;1–128. [Accessed 31 August 2008]. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar
• Gonzalez de RequenaDBonoraSCavechiaIAtazanavir Ctrough is associated with efficacy and safety at 24 weeks: Definition of therapeutic range6th International Workshop on Clinical Pharmacology of HIV TherapyApril 28–30 2005Quebec City, Quebec, Canada; Abstract 60.
   Google Scholar
• PellegrinIBreilhDRagnaudJMVirological responses to atazanavir-ritonavir-based regimens: resistance substitutions score and pharmacokinetic parameters (Reyaphar study)Antivir Ther200611442142916856615
   PubMed Web of Science ®Google Scholar
• MorseGCatanzaroLAcostaEClinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapyLancet Infect Dis20066421522516554246
   PubMed Web of Science ®Google Scholar
• WinstonAHalesGAminJThe normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individualsAIDS200519131393139916103770
   PubMed Web of Science ®Google Scholar
• Rodriguez NovoaSBarreiroPRendonAPlasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C – >T polymorphism at the multidrug resistance gene 1Clin Infect Dis200642229129516355344
   PubMed Web of Science ®Google Scholar
• Rodriguez-NovoaSMartin-CarboneroLBarreiroPGenetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemiaAIDS2007211414617148966
   PubMed Web of Science ®Google Scholar
• Rodriguez-NovoaSMorelloJGonzálezMIncrease in serum bilirubin in HIV/HCV coinfected patients on stable atazanavir therapy following initiation of peginterferon plus ribavirinAIDS2008 (in press).
   PubMed Web of Science ®Google Scholar
• TaburetAPikettyCChazallonCInteractions between atazanavir-ritonavir and tenofovir in heavily pretreated HIV-infected patientsAntimicrob Agents Chemother20044862091209615155205
   PubMed Web of Science ®Google Scholar
• JohnsonMGrinsztejnBRodriguezC96-week comparison of once-daily Atazanavir/ritonavir and twice-daily Lopinavir/ ritonavir in patients with multiple virologic failuresAIDS200620571171816514301
   PubMed Web of Science ®Google Scholar
• Rodriguez-NovoaSMorelloJBarreiroPSwitch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoringAIDS Res Hum Retroviruses200824682182518507524
   PubMed Web of Science ®Google Scholar
• BurchellBBrierleyCRanceDSpecificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidationLife Sci19955720181918317475929
   PubMed Web of Science ®Google Scholar
• ZhangDChandoTEverettDPattenCDehalSHumphreysWIn vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidationDrug Metab Dispos200533111729173916118329
   PubMed Web of Science ®Google Scholar
• HoffmeyerSBurkOvon RichterOFunctional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivoProc Natl Acad Sci U S A20009773473347810716719
   PubMed Web of Science ®Google Scholar
• KroetzDPauli-MagnusCHodgesLSequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) genePharmacogenetics200313848149412893986
   PubMedGoogle Scholar
• LambaJStromSVenkataramananRMDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotypeClin Pharmacol Ther200679432533816580901
   PubMed Web of Science ®Google Scholar
• KohleCMohrleBMunzelPFrequent co-occurrence of the TATA box mutation associated with Gilbert’s syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and EgyptiansBiochem Pharmacol20036591521152712732365
   PubMed Web of Science ®Google Scholar
• LankischTMoebiusUWehmeierMGilbert’s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotypeHepatology20064451324133217058217
   PubMed Web of Science ®Google Scholar
• RotgerMTaffePBleiberGGilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemiaJ Infect Dis200519281381138616170755
   PubMed Web of Science ®Google Scholar
• SanneIPilieroPSquiresKThiryASchnittmanSAI424–007 Clinical Trial GroupResults of a phase 2 clinical trial at 48 weeks (AI424–007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjectsJ Acquir Immune Defic Syndr2003321182912514410
   PubMed Web of Science ®Google Scholar
• MurphyRSanneICahnPDose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week resultsAIDS200317182603261414685054
   PubMed Web of Science ®Google Scholar
• GallagherDKieranJSheehanGLambertJMahonNMallonPRitonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reportsClin Infect Dis2008473e36818558878
   PubMed Web of Science ®Google Scholar
• BustiATsikourisJPeetersMA prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patientsHIV Med20067531732216945077
   PubMed Web of Science ®Google Scholar
• GianottiNGuffantiMGalliLElectrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavirAIDS200721121648165117630564
   PubMed Web of Science ®Google Scholar
• ChangHPellaPAtazanavir urolithiasisN Engl J Med2006355202158215917108352
   PubMed Web of Science ®Google Scholar
• CouzigouCDaudonMMeynardJUrolithiasis in HIV-positive patients treated with atazanavirClin Infect Dis2007458e105817879904
   PubMed Web of Science ®Google Scholar
• von HentigNAtazanavir/ritonavir: A review of its use in HIV therapyDrugs Today (Barc)200844210313218389089
   PubMed Web of Science ®Google Scholar
• MalanDKrantzEDavidNEfficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patientsJ Acquir Immune Defic Syndr20084716116717971713
   PubMed Web of Science ®Google Scholar
• HammerSEronJReissPAntiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panelJAMA200830055557018677028
   PubMed Web of Science ®Google Scholar
• CampbellTSmeatonLDe GrutollaVPEARLS (ACTG A5175): A multinational study of didanosine-EC, emtricitabine and atazanavir vs co-formulated ZDV/lamivudine and EFV for initial treatment of HIV-1 infectionXVII International AIDS Conference2008 Aug 3–8Mexico City, MexicoAbstract THAB0404.
   Google Scholar
• SmithKWeinbergWDejesusEFosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERTAIDS Res Ther20085518373851
   PubMedGoogle Scholar
• MolinaJAndrade-VillanuevaJEchevarriaJOnce-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyLancet2008372963964665518722869
   PubMed Web of Science ®Google Scholar
• HaasDZalaCSchraderSTherapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: A randomized comparative pilot trialAIDS20031791339134912799555
   PubMed Web of Science ®Google Scholar
• BoffitoMKurowskiMKruseGAtazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimenAIDS20041891291129715362661
   PubMed Web of Science ®Google Scholar
• CohenCNieto-CisnerosLZalaCComparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trialCurr Med Res Opin200521101683169216238909
   PubMed Web of Science ®Google Scholar
• JohnsonMGrinsztejnBRodriguezCAtazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresAIDS200519768569415821394
   PubMed Web of Science ®Google Scholar
• de MendozaCValerLRiberaEPerformance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patientsHIV Clin Trials20067416317117065028
   PubMed Web of Science ®Google Scholar
• GianottiNSoriaALazzarinAAntiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: A reviewNew Microbiol2007302798817619250
   PubMed Web of Science ®Google Scholar
• WoodRPhanuphakPCahnPLong-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavirJ Acquir Immune Defic Syndr200436268469215167287
   PubMed Web of Science ®Google Scholar
• SensionMGrinsztejnBMolinaJMAI424067: Improvement in lipid profiles after 12 weeks of switching to atazanavir from boosted or unboosted protease inhibitors in patients with no previous PI virologic failure and hyperlipidemia at baseline12th Conference on Retroviruses and Opportunistic Infections2005 Feb 22–25Boston, MA, USAAbstract 858.
   Google Scholar
• Bristol-Myers Squibb Company. Clinical Study Report AI424067. [Accessed 31 Aug 2008]. Available from: http://ctr.bms.com/pdf//AI424067.pdf27
   Google Scholar
• GatellJSalmon-CeronDLazzarinAEfficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424–097) 48-week resultsClin Infect Dis200744111484149217479947
   PubMed Web of Science ®Google Scholar
• SorianoVGarcia-GascoPVispoEEfficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trialJ Antimicrob Chemother200861120020517999977
   PubMed Web of Science ®Google Scholar
• MallolasJPodzamczerDDomingoPEfficacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The ATAZIP study4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention2007 July 22–25Sydney, AustraliaAbstract WEPEB117LB.
   Google Scholar
• NoorMFlintOMaaJParkerREffects of atazanavir/ ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: Demonstrable differences in vitro and clinicallyAIDS200620141813182116954722
   PubMed Web of Science ®Google Scholar
• GuffantiMCaumoAGalliLSwitching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjectsEur J Endocrinol2007156450350917389467
   PubMed Web of Science ®Google Scholar
• BustiABedimoRMargolisDHardinDImprovement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavirJ Investig Med2008562539544
   PubMed Web of Science ®Google Scholar
• JemsekJArathoonEArlottiMBody fat and other metabolic effects of atazanavir and EFV, each administered in combination with ZDV plus lamivudine, in antiretroviral-naive HIV-infected patientsClin Infect Dis200642227328016355341
   PubMed Web of Science ®Google Scholar
• HaerterGManfrasBMuellerMKernPTreinARegression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavirAIDS200418695295515060446
   PubMed Web of Science ®Google Scholar
• MoyleGGirardJAndradeJContinuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL studyXVII International AIDS Conference2008 August 3–8Mexico City, MexicoAbstract MOPDB103.
   Google Scholar
• ColafigliMDi GiambenedettoSBraccialeLTamburriniECaudaRDe LucaACardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimenHIV Med20089317217918217998
   PubMed Web of Science ®Google Scholar
• FlammerAVoNLedergerberBEffect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: Randomized controlled trialHeart(in press).
   Google Scholar
• ArribasJRPulidoFDelgadoRLopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study)J Acquir Immune Defic Syndr200540328028716249701
   PubMed Web of Science ®Google Scholar
• PulidoFArribasJRDelgadoRLopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIVAIDS2008222F1918097218
   PubMed Web of Science ®Google Scholar
• SwindellsSDiRienzoAGWilkinTRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionJAMA2006296780681416905786
   PubMed Web of Science ®Google Scholar
• KarlstromOJosephsonFSonnerborgAEarly virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapyJ Acquir Immune Defic Syndr200744441742217159658
   PubMed Web of Science ®Google Scholar
• VernazzaPDaneelSSchifferVThe role of compartment penetration in PI-monotherapy: The atazanavir-ritonavir monomaintenance (ATARITMO) trialAIDS200721101309131517545707
   PubMed Web of Science ®Google Scholar
• SahaliSChaixMLDelfraissyJFGhosnJRitonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infectionAIDS Rev200810141418385776
   PubMed Web of Science ®Google Scholar
• VoraSMarcelinAGGunthardHClinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patientsAIDS2006201354016327317
   PubMed Web of Science ®Google Scholar
• BertoliASantoroMMLorenziniPDifferent patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patientsAntivir Ther200611 suppl 1S99
   Google Scholar